10 results on '"Bolcen, Shanna"'
Search Results
2. Development of A Standardized Opsonophagocytosis Killing Assay for Group B Streptococcus and Assessment in an Interlaboratory Study.
- Author
-
Leung, Stephanie, Collett, Clare F., Allen, Lauren, Lim, Suzanna, Maniatis, Pete, Bolcen, Shanna J., Alston, Bailey, Patel, Palak Y., Kwatra, Gaurav, Hall, Tom, Thomas, Stephen, Taylor, Stephen, Le Doare, Kirsty, and Gorringe, Andrew
- Subjects
STREPTOCOCCUS agalactiae ,NATURAL immunity ,VACCINE trials ,VACCINE development ,POLYSACCHARIDES - Abstract
The placental transfer of antibodies that mediate bacterial clearance via phagocytes is likely important for protection against invasive group B Streptococcus (GBS) disease. A robust functional assay is essential to determine the immune correlates of protection and assist vaccine development. Using standard reagents, we developed and optimized an opsonophagocytic killing assay (OPKA) where dilutions of test sera were incubated with bacteria, baby rabbit complement (BRC) and differentiated HL60 cells (dHL60) for 30 min. Following overnight incubation, the surviving bacteria were enumerated and the % bacterial survival was calculated relative to serum-negative controls. A reciprocal 50% killing titer was then assigned. The minimal concentrations of anti-capsular polysaccharide (CPS) IgG required for 50% killing were 1.65–3.70 ng/mL (depending on serotype). Inhibition of killing was observed using sera absorbed with homologous CPS but not heterologous CPS, indicating specificity for anti-CPS IgG. The assay performance was examined in an interlaboratory study using residual sera from CPS-conjugate vaccine trials with international partners in the Group B Streptococcus Assay STandardisatiON (GASTON) Consortium. Strong correlations of reported titers between laboratories were observed: ST-Ia r = 0.88, ST-Ib r = 0.91, ST-II r = 0.91, ST-III r = 0.90 and ST-V r = 0.94. The OPKA is an easily transferable assay with accessible standard reagents and will be a valuable tool to assess GBS-specific antibodies in natural immunity and vaccine studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Isolation of Onchocerca lupi in dogs and black flies, California, USA
- Author
-
Hassan, Hassan K., Bolcen, Shanna, Kubofcik, Joseph, Nutman, Thomas B., Eberhard, Mark L., Middleton, Kelly, Wekesa, Joseph Wakoli, Ruedas, Gimena, Nelson, Kimberly J., Dubielzig, Richard, De Lombaert, Melissa, Silverman, Bruce, Schorling, Jamie J., Adler, Peter H., Unnasch, Thomas R., and Beeler, Emily S.
- Subjects
Cytochrome oxidase -- Analysis -- Health aspects ,Dogs -- Analysis -- Health aspects ,RNA -- Analysis -- Health aspects ,Health - Abstract
Onchocerca lupi is a zoonotic parasite capable of infecting dogs, cats, and humans. Human infection was first suspected in 2002, when a case of human subconjunctival filariasis was found to [...]
- Published
- 2015
- Full Text
- View/download PDF
4. Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020.
- Author
-
Basavaraju, Sridhar V, Patton, Monica E, Grimm, Kacie, Rasheed, Mohammed Ata Ur, Lester, Sandra, Mills, Lisa, Stumpf, Megan, Freeman, Brandi, Tamin, Azaibi, Harcourt, Jennifer, Schiffer, Jarad, Semenova, Vera, Li, Han, Alston, Bailey, Ategbole, Muyiwa, Bolcen, Shanna, Boulay, Darbi, Browning, Peter, Cronin, Li, and David, Ebenezer
- Subjects
SARS-CoV-2 ,IMMUNOGLOBULINS ,SERODIAGNOSIS ,BLOOD collection ,CELL receptors ,ENZYME-linked immunosorbent assay ,DESCRIPTIVE statistics - Abstract
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), was first identified in Wuhan, China, in December 2019, with subsequent worldwide spread. The first US cases were identified in January 2020. Methods To determine if SARS-CoV-2–reactive antibodies were present in sera prior to the first identified case in the United States on 19 January 2020, residual archived samples from 7389 routine blood donations collected by the American Red Cross from 13 December 2019 to 17 January 2020 from donors resident in 9 states (California, Connecticut, Iowa, Massachusetts, Michigan, Oregon, Rhode Island, Washington, and Wisconsin) were tested at the Centers for Disease Control and Prevention for anti–SARS-CoV-2 antibodies. Specimens reactive by pan-immunoglobulin (pan-Ig) enzyme-linked immunosorbent assay (ELISA) against the full spike protein were tested by IgG and IgM ELISAs, microneutralization test, Ortho total Ig S1 ELISA, and receptor-binding domain/ACE2 blocking activity assay. Results Of the 7389 samples, 106 were reactive by pan-Ig. Of these 106 specimens, 90 were available for further testing. Eighty-four of 90 had neutralizing activity, 1 had S1 binding activity, and 1 had receptor-binding domain/ACE2 blocking activity >50%, suggesting the presence of anti–SARS-CoV-2–reactive antibodies. Donations with reactivity occurred in all 9 states. Conclusions These findings suggest that SARS-CoV-2 may have been introduced into the United States prior to 19 January 2020. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Nocardia cyriacigeorgica Infections Attributable to Unlicensed Cosmetic Procedures—An Emerging Public Health Problem?
- Author
-
Apostolou, Andria, Bolcen, Shanna J., Dave, Vaidehi, Jani, Nisha, Lasker, Brent A., Tan, Christina G., Montana, Barbara, Brown, June M., and Genese, Carol A.
- Subjects
- *
BACTERIAL diseases , *NOCARDIA , *PUBLIC health , *EPIDEMICS , *SOFT tissue infections , *HOSPITAL care , *DEBRIDEMENT , *PLASTIC surgery , *ANTI-infective agents - Abstract
We describe an outbreak of Nocardia cyriacigeorgica soft-tissue infections attributable to unlicensed cosmetic injections and the first report using multilocus sequence typing sequence data for determining Nocardia strain relatedness in an outbreak. All 8 cases identified had a common source exposure and required hospitalization, surgical debridement, and prolonged antimicrobial therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Fatal fungal soft-tissue infections after a tornado--Joplin, Missouri, 2011
- Author
-
Benedict, Kaitlin, Adebanjo, Tolu, Harris, Julie, Lockhart, Shawn, Peterson, Joyce, McClinton, Shirley, Gade, Lalitha, Etienne, Kizee, Hurst, Steven, Benjamin, Lynette, Whitney, Anne, Bolcen, Shanna, Brandt, Mary, Park, Benjamin, Turabelidze, George, Bos, John, Hedrick, Eddie, Byrd, David, Fanfair, Robyn Neblett, Bennett, Sarah, and Lo, Yi-Chun
- Subjects
Disaster victims -- Health aspects ,Tornadoes -- Health aspects ,Cross infection -- Health aspects ,Nosocomial infections -- Health aspects ,Health - Abstract
On May 22, 2011, at 5:34 p.m. a tornado with winds >200 mph struck Joplin, Missouri, injuring approximately 1,000 persons and causing 159 deaths. On June 3, a local physician [...]
- Published
- 2011
7. Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six-group B streptococcus polysaccharides.
- Author
-
Le Doare K, Gaylord MA, Anderson AS, Andrews N, Baker CJ, Bolcen S, Felek A, Giardina PC, Grube CD, Hall T, Hallis B, Izu A, Madhi SA, Maniatis P, Matheson M, Mawas F, McKeen A, Rhodes J, Alston B, Patel P, Schrag S, Simon R, Tan CY, Taylor S, Kwatra G, and Gorringe A
- Subjects
- Infant, Humans, Reproducibility of Results, Immunoassay, Polysaccharides, Streptococcus agalactiae, Immunoglobulin G, Guillain-Barre Syndrome
- Abstract
Measurement of IgG antibodies against group B streptococcus (GBS) capsular polysaccharide (CPS) by use of a standardized and internationally accepted multiplex immunoassay is important for the evaluation of candidate maternal GBS vaccines in order to compare results across studies. A standardized assay is also required if serocorrelates of protection against invasive GBS disease are to be established in infant sera for the six predominant GBS serotypes since it would permit the comparison of results across the six serotypes. We undertook an interlaboratory study across five laboratories that used standardized assay reagents and protocols with a panel of 44 human sera to measure IgG antibodies against GBS CPS serotypes Ia, Ib, II, III, IV, and V. The within-laboratory intermediate precision, which included factors like the lot of coated beads, laboratory analyst, and day, was generally below 20% relative standard deviation (RSD) for all six serotypes, across all five laboratories. The cross-laboratory reproducibility was < 25% RSD for all six serotypes, which demonstrated the consistency of results across the different laboratories. Additionally, anti-CPS IgG concentrations for the 44-member human serum panel were established. The results of this study showed assay robustness and that the resultant anti-CPS IgG concentrations were reproducible across laboratories for the six GBS CPS serotypes when the standardized assay was used.
- Published
- 2024
- Full Text
- View/download PDF
8. Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel.
- Author
-
Lester SN, Stumpf M, Freeman BD, Mills L, Schiffer J, Semenova V, Jia T, Desai R, Browning P, Alston B, Ategbole M, Bolcen S, Chen A, David E, Manitis P, Tatum H, Qin Y, Zellner B, Drobeniuc J, Tejada-Strop A, Chatterjee P, Shrivastava-Ranjan P, Jenks MH, McMullan LK, Flint M, Spiropoulou CF, Niemeyer GP, Werner BJ, Bean CJ, Johnson JA, Hoffmaster AR, Satheshkumar PS, Schuh AJ, Owen SM, and Thornburg NJ
- Abstract
Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) is a novel human coronavirus that was identified in 2019. SARS-CoV-2 infection results in an acute, severe respiratory disease called coronavirus disease 2019 (COVID-19). The emergence and rapid spread of SARS-CoV-2 has led to a global public health crisis, which continues to affect populations across the globe. Real time reverse transcription polymerase chain reaction (rRT-PCR) is the reference standard test for COVID-19 diagnosis. Serological tests are valuable tools for serosurveillance programs and establishing correlates of protection from disease. This study evaluated the performance of one in-house enzyme linked immunosorbent assay (ELISA) utilizing the pre-fusion stabilized ectodomain of SARS-CoV-2 spike (S), two commercially available chemiluminescence assays Ortho VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Abbott SARS-CoV-2 IgG assay and one commercially available Surrogate Virus Neutralization Test (sVNT), GenScript USA Inc., cPass SARS-CoV-2 Neutralization Antibody Detection Kit for the detection of SARS-CoV-2 specific antibodies. Using a panel of rRT-PCR confirmed COVID-19 patients' sera and a negative control group as a reference standard, all three immunoassays demonstrated high comparable positivity rates and low discordant rates. All three immunoassays were highly sensitive with estimated sensitivities ranging from 95.4-96.6 %. ROC curve analysis indicated that all three immunoassays had high diagnostic accuracies with area under the curve (AUC) values ranging from 0.9698 to 0.9807. High positive correlation was demonstrated among the conventional microneutralization test (MNT) titers and the sVNT inhibition percent values. Our study indicates that independent evaluations are necessary to optimize the overall utility and the interpretation of the results of serological tests. Overall, we demonstrate that all serological tests evaluated in this study are suitable for the detection of SARS-CoV-2 antibodies., Competing Interests: ‘The author(s) declare that there are no conflicts of interest’. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Names of specific vendors, manufacturers, or products are included for public health and informational purposes; inclusion does not imply endorsement of the vendors, manufacturers, or products by the Centers for Disease Control and Prevention or the US Department of Health and Human Services.
- Published
- 2024
- Full Text
- View/download PDF
9. Gordonia bronchialis bacteremia and pleural infection: case report and review of the literature.
- Author
-
Johnson JA, Onderdonk AB, Cosimi LA, Yawetz S, Lasker BA, Bolcen SJ, Brown JM, and Marty FM
- Subjects
- Actinomycetales classification, Actinomycetales genetics, Actinomycetales Infections microbiology, Bacteremia complications, Bacteremia microbiology, Bacteremia pathology, Blood microbiology, DNA, Bacterial chemistry, DNA, Bacterial genetics, DNA, Ribosomal chemistry, DNA, Ribosomal genetics, Female, Humans, Microscopy, Middle Aged, Molecular Sequence Data, Pleurisy complications, Pleurisy microbiology, Pleurisy pathology, RNA, Ribosomal, 16S genetics, Radiography, Thoracic, Sequence Analysis, DNA, Tomography, X-Ray Computed, Actinomycetales isolation & purification, Actinomycetales Infections diagnosis, Actinomycetales Infections pathology, Bacteremia diagnosis, Pleurisy diagnosis
- Abstract
Gordonia species are aerobic actinomycetes recently recognized as causing human disease, often in the setting of intravascular catheter-related infections. We describe a case of Gordonia bronchialis bacteremia and pleural space infection in the absence of an indwelling intravascular catheter and review the breadth of reported infections with this emerging pathogen.
- Published
- 2011
- Full Text
- View/download PDF
10. Characterization of extended-spectrum cephalosporin-resistant Salmonella enterica serovar Heidelberg isolated from humans in the United States.
- Author
-
Folster JP, Pecic G, Bolcen S, Theobald L, Hise K, Carattoli A, Zhao S, McDermott PF, and Whichard JM
- Subjects
- Base Sequence, Cluster Analysis, DNA, Bacterial analysis, Dose-Response Relationship, Drug, Food Microbiology, Humans, Microbial Sensitivity Tests, Plasmids, Polymerase Chain Reaction, Salmonella Food Poisoning microbiology, Salmonella enterica classification, Salmonella enterica enzymology, Salmonella enterica genetics, Serotyping, United States, beta-Lactamases genetics, Anti-Bacterial Agents pharmacology, Cephalosporins pharmacology, Drug Resistance, Bacterial genetics, Meat microbiology, Salmonella enterica drug effects
- Abstract
During the past decade, extended-spectrum cephalosporin resistance has increased among human isolates of Salmonella enterica serovar Heidelberg, the fourth most common serotype in the United States. We therefore characterized 54 Heidelberg isolates with decreased susceptibility (minimum inhibitory concentrations >or=2 mg/L) to ceftriaxone or ceftiofur; 49 (90.7%) contained the CMY-type beta-lactamase (bla(CMY)) gene. The 49 bla(CMY)-positive human Heidelberg isolates demonstrated a high degree of relatedness; 4 clusters (25 isolates total) had indistinguishable XbaI and BlnI patterns by pulsed-field gel electrophoresis and were indistinguishable from 42 retail meat Heidelberg isolates. Further characterization of 15 of these isolates demonstrated that all of the bla genes were bla(CMY-2) and plasmid-encoded, and most (11/15) of the plasmids were approximately 100 kb in size and belong to the incompatibility group I1 (IncI1). All five IncI1 plasmids tested by plasmid multilocus sequence typing analysis were ST12. This report suggests that extended-spectrum cephalosporin resistance among human Heidelberg isolates is mediated by the spread of a common IncI1 bla(CMY-2) plasmid, which may have a preference for a particular genetic background.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.